Dr. Robert Spiegel is an independent director at Geron, a late-stage clinical biopharmaceutical company. He has served on the company’s board since 2010.
Dr. Spiegel serves on various other boards, including Athenex, Sun Pharma, Ayala Pharmaceuticals, and Cyclacel Pharmaceuticals. He is a professor at Weill Cornell Medicine and a fellow at the University of Pennsylvania’s Center for Bioethics.
In addition to board service, Dr. Spiegel engages in private equity consulting, as CEO of his firm, Spiegel Consulting. He also serves as a senior advisor to private equity firm, Warburg Pincus, and to the venture investment fund, Israel Biotech. Over the years, he has gained meaningful R&D, clinical, and operational experience in the biopharmaceutical industry—including biotech, big pharma, and academic startups.
Dr. Spiegel was previously the chief medical officer for PTC Therapeutics, as well as a director for both Cancer Care New Jersey and the Cancer Institute of New Jersey.
Other significant experience includes 26 years at Schering-Plough (now Merck & Co.). He joined the company as its director of clinical research in oncology, and later advanced to other senior positions in clinical research. His last role at Schering-Plough was chief medical officer, where he presided over at least 30 drug applications for FDA approval, participated in due diligence surveys, re-engineered pharmacovigilance and risk management, and established a quality framework for research operations, among other responsibilities.
Early on in his career, following an internal medicine residency, Dr. Spiegel took a medical oncology fellowship with the National Cancer Institute, and he ended up holding academic positions both there and at the New York University Cancer Center for nearly 20 years.
Dr. Spiegel earned his B.A. at Yale University and his M.D. at the University of Pennsylvania. He went through his specialty training at the NCI, NIH.
What is Robert J. Spiegel's net worth?
The estimated net worth of Robert J. Spiegel is at least $395,862.08 as of September 13th, 2018. Dr. Spiegel owns 110,576 shares of Geron stock worth more than $395,862 as of April 25th. This net worth estimate does not reflect any other investments that Dr. Spiegel may own. Learn More about Robert J. Spiegel's net worth.
How do I contact Robert J. Spiegel?
Has Robert J. Spiegel been buying or selling shares of Geron?
Robert J. Spiegel has not been actively trading shares of Geron during the last ninety days. Most recently, Robert J. Spiegel sold 175,000 shares of the business's stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $6.85, for a transaction totalling $1,198,750.00. Following the completion of the sale, the director now directly owns 110,576 shares of the company's stock, valued at $757,445.60. Learn More on Robert J. Spiegel's trading history.
Are insiders buying or selling shares of Geron?
During the last twelve months, Geron insiders bought shares 1 times. They purchased a total of 6,607 shares worth more than $15,063.96. During the last twelve months, insiders at the biopharmaceutical company sold shares 2 times. They sold a total of 70,000 shares worth more than $191,800.00. The most recent insider tranaction occured on August, 24th when Director Elizabeth G O'farrell bought 6,607 shares worth more than $15,063.96. Insiders at Geron own 3.1% of the company.
Learn More about insider trades at Geron. Information on this page was last updated on 8/24/2023.
